Dianthus Therapeutics (NASDAQ:DNTH) CEO Marino Garcia Sells 122,918 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $10,016,587.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH traded down $2.46 during midday trading on Friday, reaching $77.86. The stock had a trading volume of 2,278,752 shares, compared to its average volume of 1,180,013. The stock has a market capitalization of $3.46 billion, a P/E ratio of -18.99 and a beta of 1.56. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $88.02. The firm’s fifty day simple moving average is $52.53 and its 200-day simple moving average is $42.56.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. On average, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of recent research reports. Robert W. Baird lifted their target price on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday. Jefferies Financial Group set a $98.00 target price on Dianthus Therapeutics and gave the company a “buy” rating in a research note on Monday. Wedbush lifted their price target on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday. Oppenheimer increased their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $115.33.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Parkside Financial Bank & Trust grew its holdings in shares of Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Dianthus Therapeutics in the fourth quarter valued at about $40,000. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics in the second quarter valued at about $27,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics during the third quarter worth about $64,000. Finally, Royal Bank of Canada grew its stake in Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.